Rethinking roadtrips

Texas startup using Tesla cars for more efficient and eco-friendly travel

ElecTrip uses eco-friendly Teslas to shuttle business people to and fro across the state. Courtesy of Electrip

A Texas startup shuffling business men and women across the state in style has created an elevated road trip experience for its customers.

Founded in 2018 and based in Austin, ElecTrip aims to add luxury and convenience to regional commutes between major Texas cities by providing transportation in Teslas equipped with WiFi, complimentary snacks, and professional drivers.

Mandeep Patel, a University of Texas at Austin student, had the idea for the company just about a year ago while completing an internship. Patel had the company up and running just a few months later.

Patel serves as founder and CEO, along with his classmate and co-founder, Eliott Lee, who is COO. Lee tells InnovationMap that he and Patel had gotten tired of the stress of airport travel, the restrictive schedule of buses, and the soul-draining fatigue of driving. ElecTrip's no-compromise solution is cost effective, comfortable, and carbon neutral.

"One thing we really pride ourselves on is being sustainable, energy-efficient, and having no emissions," Lee says.

ElecTrip offers door-to-door service for their customers, who can customize pickup and drop-off locations in any major Texas city. The company has eight routes between Houston, Austin, Dallas, and San Antonio, but customers can book a custom route within a 300-mile radius of those cities. Prices range from $249.99 to $429.99, but customers can opt to share rides to cut down on cost, with cars seating three to five riders.

"We emphasize on B2B, geared more towards businesses," says Lee, explaining that customers can customize their trip with food and beverage requests.

The company offers three different Tesla models: Tesla Model S, Tesla Model X, and Tesla Model 3, each offering a specific number of passenger seats, luggage capacity, and mileage range.

"The main reason why we chose Tesla is because of the supercharger network," says Lee in referring to Tesla's 1,422 Supercharger Stations throughout the United States.

Clients don't have to worry about the charging process, Lee says. The company plans the trips around these charging stations, which are free to any Tesla user.

ElecTrip is less than a year old and has already coordinated hundreds of rides, according to the website. While starting the company while still juggling classes — Lee expects to graduate from UT in 2020, while Patel is graduating this year — Lee says being a student-run startup has its perks.

"We find a lot of funding in startup competitions that only students have access to," said Lee.

Additional initial funding for the company came out of Patel's savings account, Lee says. ElecTrip owns one Tesla and rents out additional vehicles to cover the demand of rides. Lee explains that renting vehicles instead of owning them would cut back on the company's real estate while providing additional income for Tesla owners that aren't using their cars.

Patel and Lee are the only two full-time employees at ElecTrip, as all drivers work on a contract-basis. Lee tells InnovationMap that in the future, ElecTrip will focus on business partnerships.

"A lot of these other services are geared towards consumers," says Lee. "We hope to be geared toward mainly towards businesses in the long run."

ElecTrip is gearing up for growing its partnerships with local small businesses in Austin and Houston to provide food and drink products for rides.

"It is something we're looking at targeting in the next one or two months," says Lee.

Mandeep Patel (left) and Eliott Lee are the co-founders of ElecTrip, a travel company that uses Teslas across Texas.Courtesy of ElecTrip

Houston-based Moleculin has three different oncology technologies currently in trials. Getty Images

Immunotherapy and personalized medicine get all the headlines lately, but in the fight against cancer, a natural compound created by bees could beat them in winning one battle.

In 2007, chairman and CEO Walter Klemp founded Moleculin Biotech Inc. as a private company. The former CPA had found success in life sciences with a company that sold devices for the treatment of acne. That introduction into the field of medical technology pushed him toward more profound issues than spotty skin.

"Coincidentally, the inventor of that technology had a brother who was a neuro-oncologist at MD Anderson," Klemp recalls.

The since-deceased Dr. Charles Conrad slowly lured Klemp into what he calls the "cancer ecosphere" of MD Anderson. In 2016, the company went public. And it looks like sooner rather than later, it could make major inroads against some of the toughest cancers to beat.

Klemp observed that while Houston has the world's largest medical center, "the tragic irony" is that other cities have far more biotech money ready to be invested.

"The Third Coast is really starved for capital," he says. "What drew me into this was I was one of the few entrepreneurs that lived here that knew the ropes in terms of tapping into East and West Coast capital structures and could make that connection for them."

The company has three core technologies currently being tested with some success, but the most promising is called WP1066, named for researcher Waldemar Priebe, "a rock star" in his native Poland, according to Klemp, who works at MD Anderson. Though Priebe came to the U.S. in the 1980s, he is still an adjunct professor at the University of Warsaw and conducts some of his trials in Poland because it's easier to get grant money there.

WP1066 uses propolis, a compound of beeswax, sap and saliva that bees produce to seal small areas of their hives, as a base. The molecular compound that Priebe discovered affects STAT3 (signal transducer and activator of transcription), a transcription factor that encourages tumor development. In short, the active compound in WP1066 both downregulates the STAT3, a long-time Holy Grail in the cancer research world, and directly attacking the tumor, but also quieting T Cells, which allows the body's own immune system to fight the cancer itself. Essentially, it works both as chemotherapy and immunotherapy.

WP1066 is demonstrating drug-like properties in trials at MD Anderson on glioblastoma, the aggressive brain cancer that recently took the life of the hospital's former president, John Mendelsohn, as well as John McCain and Beau Biden. It is also being tested against pancreatic cancer, one of the most virulent killers cancer doctors combat.

Priebe also created Annamycin, named for his oldest daughter, a first-line chemotherapy drug that fights Acute Myeloid Leukemia without the cardiotoxicity that can damage patients' hearts even as they beat their cancer.

WP1122 uses yet another mechanism to fight cancer.

"Most people don't know that morphine is essentially a modified version of heroin," Klemp explains.

The difference between the poppy-based drugs? Heroin can cross the blood-brain barrier. It's described as the dicetyl ester of morphine. WP1122 is the dicetyl ester of 2DG (2-Deoxyglucose), a glycolysis inhibitor, which works by overfilling tumor cells with fake glucose so that they can't consume the real glucose that makes them grow.

"The theory is, we could feed you so full of junk food that eventually you'd starve to death," Klemp elucidates. It can cross the blood-brain barrier and is metabolized slowly, meaning that it can be made into a drug in a way that 2DG cannot.

What's impressive about Moleculin is its diversity of drugs. Most companies have one drug that gets all or most of the attention. Moleculin has strong hopes for all three currently in trials.

"It's essentially multiple shots on the goal," says executive vice president and CFO Jonathan Foster.

Moleculin has 13 total employees, five of whom are based in Houston. An office in the Memorial Park area serves as a landing pad for employees and collaborators from around the world to get their work done when in Space City. The virtual office set-up works for the company because experts can stay in their home cities to get their work done. And that work is on its way to saving scores of lives.